Meflynate Xl (Methylphenidate Hydrochloride)

Methylphenidate blocks the reuptake transporters for dopamine and norepinephrine, increasing the amount of these neurotransmitters in the synaptic cleft. The heightened dopaminergic and noradrenergic signaling in brain regions that regulate attention and arousal leads to improved concentration and reduced sleepiness.

The appropriate dose of Meflynate Xl is individualized by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and response to therapy. Dosage adjustments are made according to clinical effectiveness and tolerability, following local prescribing guidelines.

Safety data for methylphenidate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified health professional after a thorough risk‑benefit assessment.

To request Meflynate Xl, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Meflynate Xl (methylphenidate) and amphetamine‑based stimulants share a similar mechanism of increasing dopamine and norepinephrine activity, but methylphenidate primarily blocks reuptake, whereas amphetamines also promote release. Individual response, side‑effect profile, and potential for abuse differ, so clinicians choose the agent that best matches a patient’s clinical situation.

Store Meflynate Xl at ambient temperature, preferably below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat. Ensure the container is tightly closed to maintain stability and prevent accidental ingestion.

Meflynate Xl is taken orally. The tablet should be swallowed whole with a full glass of water, preferably in the morning or early afternoon to reduce the risk of insomnia. Doses are adjusted by the prescriber, and the medication should be taken exactly as directed.

Serious risks include cardiovascular events such as hypertension or arrhythmia, psychiatric effects like new or worsening psychosis, severe allergic reactions, and the potential for dependence or abuse. Patients should seek immediate medical attention if they experience chest pain, severe headache, hallucinations, or signs of an allergic reaction.

Meflynate Xl is contraindicated in individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors (MAOIs) within the past 14 days, patients with severe cardiovascular disorders, uncontrolled hypertension, or a history of serious psychiatric conditions such as psychosis. It should also be avoided in patients with marked anxiety, agitation, or a known risk of substance abuse.